Ophthalmological features of Parkinson disease

Barbara Nowacka, Wojciech Lubinski, Krystyna Honczarenko, Andrzej Potemkowski, Krzysztof Safranow, Barbara Nowacka, Wojciech Lubinski, Krystyna Honczarenko, Andrzej Potemkowski, Krzysztof Safranow

Abstract

Background: The aim of this study was to determine the type and frequency of ophthalmologic changes occurring in patients with Parkinson disease (PD).

Material/methods: One hundred consecutive patients (196 eyes) with idiopathic PD and a control group consisting of 100 healthy patients (196 eyes) matched for age and sex underwent a complete ophthalmological examination of both eyes, including assessment of patient medical history, dry eye questionare, and visual hallucinations questionnaire, distance and near best corrected visual acuity (DBCVA, NBCVA), color vision, distance photopic contrast sensitivity, near point of convergence, slit lamp examination of the eye anterior segment, tear film osmolarity and breakup time, aqueous tear production, and intraocular pressure, as well as fundus examination and evaluation of the perimacular retinal thickness (RT) and peripapillary retinal nerve fiber layer (RNFL) thickness.

Results: In the eyes of PD patients DBCVA, NBCVA, contrast sensitivity, and color discrimination were significantly reduced. We also detected increased frequency of convergence insufficiency, seborrhoic blepharitis, meibomian gland disease (MGD), dry eye syndrome, nuclear and posterior subcapsular cataract, and glaucoma (p<0.05). However, intraocular pressure (IOP) was significantly lower in the PD group compared to controls. The frequency of visual hallucinations, age-related macular degeneration (ARMD), and other ophthalmological diseases, as well as RT and RNFL thickness, did not significantly differ between investigated groups.

Conclusions: Clinicians need to be aware of the association between PD and ophthalmological changes. Restoration of good-quality vision has a great impact on PD patients' quality of life, reduction of costs of treatment and care, and rehabilitation.

References

    1. Djamgoz MB, Hankins MW, Hirano J, Archer SN. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res. 1997;37:3509–29.
    1. Biousse V, Skibell BC, Watts RL, et al. Ophthalmologic features of Parkinson’s disease. Neurology. 2004;62:177–80.
    1. Tamer C, Melek IM, Duman T, Oksüz H. Tear film tests in Parkinson’s disease patients. Ophthalmology. 2005;112:1795.
    1. Bagheri H, Berlan M, Senard JM, et al. Lacrimation in Parkinson’s disease. Clin Neuropharmacol. 1994;17:89–91.
    1. Kwon OY, Kim SH, Kim JH, et al. Schrimer test in Parkinson’s disease. J Korean Med Sci. 1994;9:239–42.
    1. Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease. Am J Ophthalmol. 2002;133:135–37.
    1. Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in Parkinson’s disease. Vision Res. 2005;45:1285–96.
    1. de Maindreville AD, Fénelon G, Mahieux F. Hallucinations in Parkinson’s disease: a follow-up study. Mov Disord. 2005;20:212–17.
    1. Barnes J, David AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70:727–33.
    1. Armstrong IT, Chan F, Riopelle RJ, Munoz DP. Control of saccades in Parkinson’s disease. Brain Cogn. 2002;49:198–201.
    1. Chan F, Armstrong IT, Pari G, et al. Deficits in saccadic eye-movement control in Parkinson’s disease. Neuropsychologia. 2005;43:784–96.
    1. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia. Mov Disord. 2011;26:2387–95.
    1. Pieri V, Diederich NJ, Raman R, Goetz CG. Decreased color discrimination and contrast sensitivity in Parkinson’s disease. J Neurol Sci. 2000;172:7–11.
    1. Uc EY, Rizzo M, Anderson SW, et al. Visual dysfunction in Parkinson disease without dementia. Neurology. 2005;65:1907–13.
    1. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson’s disease. Neurology. 1992;42:887–90.
    1. Bron AJ, Benjamin L, Snibson GR. Meibomian gland disease. Classification and grading of lid changes. Eye (Lond) 1991;5:395–411.
    1. Wink B, Harris J. A model of the Parkinsonian visual system: support for the dark adaptation hypothesis. Vision Res. 2000;40:1937–46.
    1. Dubocovich ML. Role of Melatonin in Retina. Progress in Retinal Research. 1988:129–51.
    1. Nguyen-Legros J, Versaux-Botteri C, Vernier P. Dopamine receptor localization in the mammalian retina. Mol Neurobiol. 1999;19:181–204.
    1. Linden R. The anti-death league: associative control of apoptosis in developing retinal tissue. Brain Res Brain Res Rev. 2000;32:146–58.
    1. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Retinal thickness in Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:431–36.
    1. Armstrong RA. Visual symptoms in Parkinson’s disease. Parkinsons Dis. 2011;2011:908306.
    1. Sacca SC, Bolognesi C, Battistella A, et al. Gene-environment interactions in ocular diseases. Mutat Res. 2009;66:98–117.
    1. Almer Z, Klein KS, Marsh L, et al. Ocular motor and sensory function in Parkinson’s disease. Ophthalmology. 2012;119:178–82.
    1. Onofrj M, Bonanni L, Albani G, et al. Visual hallucinations in Parkinson’s disease: clues to separate origins. J Neurol Sci. 2006;248:143–50.
    1. Matsui H, Udaka F, Tamura A, et al. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2006;19:36–40.
    1. Diederich NJ, Goetz CG, Raman R, et al. Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol. 1998;21:289–95.
    1. Kandel ER, Schwartz, Jessell TM. Principles of Neural Science. 3rd ed. New York: Elsevier; 1991.
    1. Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol. 2002;59:807–11.
    1. Costarides AP, Riley MV, Green K. Roles of catalase and the glutathione redox cycle in the regulation of anterior-chamber hydrogen peroxide. Ophthalmic Res. 1991;23:284–94.
    1. Perry TL, Godin DV, Hansen S. Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett. 1982;33:305–10.
    1. Njie-Mbye YF, Kulkarni-Chitnis M, Opere CA, et al. Lipid peroxidation: pathophysiological and pharmacological implications in the eye. Front Physiol. 2013;4:366.
    1. Tsironi EE, Dastiridou A, Katsanos A, et al. Perimetric and retinal nerve fiber layer findings in patients with Parkinson’s disease. BMC Ophthalmol. 2012;12:54.
    1. Yenice O, Onal S, Midi I, et al. Visual field analysis in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2008;14:193–98.
    1. McKinnon SJ. Glaucoma, apoptosis, and neuroprotection. Curr Opin Ophthalmol. 1997;8:28–37.
    1. Garcia-Martin E, Rodriguez-Mena D, Satue M, et al. Electrophysiology and optical coherence tomography to evaluate Parkinson disease severity. Invest Ophthalmol Vis Sci. 2014;55:696–705.
    1. Satue M, Seral M, Otin S, et al. Retinal thinning and correlation with functional disability in patients with Parkinson’s disease. Br J Ophthalmol. 2014;98:350–55.
    1. Altinaş O, Iseri PK, Tokay T, Yüksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol. 2006;26:18–24.
    1. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res. 2004;44:2793–97.
    1. Albrecht P, Müller AK, Südmeyer M, et al. Optical coherence tomography in parkinsonian syndromes. PLoS One. 2012;7:e34891.
    1. Aaker GD, Myung JS, Ehrlich JR, et al. Detection of retinal changes in Parkinson’s disease with spectral-domain optical coherence tomography. Clin Ophthalmol. 2010;4:1427–32.
    1. Chung SD, Ho JD, Hu CC, et al. Increased risk of Parkinson disease following a diagnosis of neovascular age-related macular degeneration: a retrospective cohort study. Am J Ophthalmol. 2014;157:464–69.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner